{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:03Z","timestamp":1787067543887,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.phrs.2020.104703","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:36:33Z","timestamp":1581680193000},"page":"104703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Epigenetic histone modulations of PPAR\u03b3 and related pathways contribute to olanzapine-induced metabolic disorders"],"prefix":"10.1016","volume":"155","author":[{"given":"Yueqing","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2020.104703_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40261-019-00751-2","article-title":"Association of first- vs. Second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis","volume":"39","author":"Buhagiar","year":"2019","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.phrs.2020.104703_bib0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"3","key":"10.1016\/j.phrs.2020.104703_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tem.2019.01.003","article-title":"Pozzi M. Antipsychotics promote metabolic disorders disrupting cellular lipid metabolism and trafficking","volume":"30","author":"Vantaggiato","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"issue":"643","key":"10.1016\/j.phrs.2020.104703_bib0020","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"Chen","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.phrs.2020.104703_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","article-title":"Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology","volume":"101","author":"Rojo","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2020.104703_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0035","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41598-017-02884-w","article-title":"Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104703_bib0040","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/NDT.S208061","article-title":"Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review","volume":"15","author":"Xu","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/j.2040-4603.2017.tb00753.x","article-title":"Transcriptional regulation of adipogenesis","volume":"7","author":"Mota de Sa","year":"2017","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"issue":"8","key":"10.1016\/j.phrs.2020.104703_bib0055","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1128\/MCB.19.8.5495","article-title":"Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1\/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism","volume":"19","author":"Fajas","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2020.104703_bib0060","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1073\/pnas.95.8.4333","article-title":"ADD1\/SREBP1 activates PPARgamma through the production of endogenous ligand","volume":"95","author":"Kim","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"10.1016\/j.phrs.2020.104703_bib0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2014.04.001","article-title":"PPARgamma and the global map of adipogenesis and beyond","volume":"25","author":"Lefterova","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ydbio.2012.10.031","article-title":"Role of kruppel-like transcription factors in adipogenesis","volume":"373","author":"Wu","year":"2013","journal-title":"Dev. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104703_bib0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12199-010-0193-7","article-title":"Constitutively active Stat5A and Stat5B promote adipogenesis","volume":"16","author":"Wakao","year":"2011","journal-title":"Environ. Health Prev. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00125-016-4152-8","article-title":"Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice","volume":"60","author":"Kaltenecker","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.phrs.2020.104703_bib0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41401-019-0212-1","article-title":"Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway","author":"Liu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Ferno","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"issue":"6","key":"10.1016\/j.phrs.2020.104703_bib0095","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","article-title":"Olanzapine depot exposure in male rats: dose-dependent lipogenic effects without concomitant weight gain","volume":"25","author":"Ferno","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0100","first-page":"3","article-title":"Signaling, epigenetic and TranscriptionalRegulation of hepatic lipogenesis","volume":"1","author":"Ho","year":"2017","journal-title":"J Metab."},{"issue":"6","key":"10.1016\/j.phrs.2020.104703_bib0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/1389203717666160627082444","article-title":"From histones to RNA: role of methylation in signal proteins involved in adipogenesis","volume":"18","author":"Wang","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2020.104703_bib0110","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/epi.26027","article-title":"Epigenetic developmental programs and adipogenesis: implications for psychotropic induced obesity","volume":"8","author":"Chase","year":"2013","journal-title":"Epigenetics."},{"issue":"4","key":"10.1016\/j.phrs.2020.104703_bib0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ijos.2015.41","article-title":"Histone methyltransferases and demethylases: regulators in balancing osteogenic and adipogenic differentiation of mesenchymal stem cells","volume":"7","author":"Deng","year":"2015","journal-title":"Int. J. Oral Sci."},{"issue":"12","key":"10.1016\/j.phrs.2020.104703_bib0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS Drugs"},{"issue":"0","key":"10.1016\/j.phrs.2020.104703_bib0125","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0130","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1038\/ncomms4230","article-title":"A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages","volume":"5","author":"Yu","year":"2014","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.phrs.2020.104703_bib0135","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0024-3205(02)02506-7","article-title":"Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes","volume":"72","author":"Vatamaniuk","year":"2003","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.phrs.2020.104703_bib0140","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.phrs.2020.104703_bib0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2013.08.005","article-title":"Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density","volume":"47","author":"Lian","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0150","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2020.104703_bib0155","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1007\/s11095-011-0477-7","article-title":"Mechanism-based pharmacokinetic\u2013Pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats","volume":"28","author":"Johnson","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2020.104703_bib0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"issue":"3","key":"10.1016\/j.phrs.2020.104703_bib0165","first-page":"436","article-title":"QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist","volume":"24","author":"Liu","year":"2015","journal-title":"Eur. J. Cancer Care"},{"issue":"5","key":"10.1016\/j.phrs.2020.104703_bib0170","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1096\/fj.201700997R","article-title":"Reduced PPARgamma2 expression in adipose tissue of male rat offspring from obese dams is associated with epigenetic modifications","volume":"32","author":"Lecoutre","year":"2018","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1172\/JCI200420964","article-title":"Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma","volume":"114","author":"Tsai","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"6764","key":"10.1016\/j.phrs.2020.104703_bib0180","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.phrs.2020.104703_bib0185","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.2337\/db15-1422","article-title":"Fat mass reduction with adipocyte hypertrophy and insulin resistance in heterozygous PPARgamma mutant rats","volume":"65","author":"Gumbilai","year":"2016","journal-title":"Diabetes."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4161\/org.6.1.11121","article-title":"Role of histone methylation and demethylation in adipogenesis and obesity","volume":"6","author":"Okamura","year":"2010","journal-title":"Organogenesis."},{"issue":"4","key":"10.1016\/j.phrs.2020.104703_bib0195","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molcel.2015.10.025","article-title":"H3K4\/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation","volume":"60","author":"Matsumura","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2020.104703_bib0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2045-3701-4-29","article-title":"Transcriptional and epigenetic regulation of PPARgamma expression during adipogenesis","volume":"4","author":"Lee","year":"2014","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/emboj.2012.306","article-title":"Histone H3K9 methyltransferase G9a represses PPARgamma expression and adipogenesis","volume":"32","author":"Wang","year":"2013","journal-title":"EMBO J."},{"issue":"49","key":"10.1016\/j.phrs.2020.104703_bib0210","doi-asserted-by":"crossref","first-page":"19229","DOI":"10.1073\/pnas.0810100105","article-title":"Targeted inactivation of MLL3 histone H3\u2013Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis","volume":"105","author":"Lee","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2020.104703_bib0215","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01503","article-title":"H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation","volume":"2","author":"Lee","year":"2013","journal-title":"eLife."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/emboj.2012.320","article-title":"Double SET point: G9a makes its mark in adipogenesis","volume":"32","author":"Cristancho","year":"2013","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.phrs.2020.104703_bib0225","doi-asserted-by":"crossref","first-page":"E990","DOI":"10.1152\/ajpendo.00608.2012","article-title":"G9a is transactivated by C\/EBPbeta to facilitate mitotic clonal expansion during 3T3-L1 preadipocyte differentiation","volume":"304","author":"Li","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2020.104703_bib0230","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2337\/db12-0628","article-title":"Epigenetic regulation of adipogenesis by PHF2 histone demethylase","volume":"62","author":"Okuno","year":"2013","journal-title":"Diabetes."},{"issue":"24","key":"10.1016\/j.phrs.2020.104703_bib0235","doi-asserted-by":"crossref","first-page":"E5566","DOI":"10.1073\/pnas.1721814115","article-title":"KDM4B protects against obesity and metabolic dysfunction","volume":"115","author":"Cheng","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"443","key":"10.1016\/j.phrs.2020.104703_bib0240","article-title":"Commentary: the histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity","volume":"9","author":"Barbaro","year":"2018","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0245","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncomms1755","article-title":"FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure","volume":"3","author":"Hino","year":"2012","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2020.104703_bib0250","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/emboj.2011.65","article-title":"Extensive chromatin remodelling and establishment of transcription factor\u2019 hotspots\u2019 during early adipogenesis","volume":"30","author":"Siersbaek","year":"2011","journal-title":"EMBO J."},{"issue":"22","key":"10.1016\/j.phrs.2020.104703_bib0255","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1021\/acs.jmedchem.6b01340","article-title":"Probing the Complex Binding Modes of the PPARgamma Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluorome thyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy","volume":"59","author":"Hughes","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104703_bib0260","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/254560","article-title":"Identification of Bexarotene as a PPARgamma antagonist with HDX","volume":"2015","author":"Marciano","year":"2015","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2004.11.005","article-title":"Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation","volume":"1","author":"Oishi","year":"2005","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2020.104703_bib0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cdd.2010.100","article-title":"Kruppel-like factor KLF9 regulates PPARgamma transactivation at the middle stage of adipogenesis","volume":"18","author":"Pei","year":"2011","journal-title":"Cell Death Differ."},{"issue":"13","key":"10.1016\/j.phrs.2020.104703_bib0275","doi-asserted-by":"crossref","first-page":"12867","DOI":"10.1074\/jbc.M410515200","article-title":"Role of Kruppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis","volume":"280","author":"Mori","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2020.104703_bib0280","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1101\/gad.1240705","article-title":"Hic-5 regulates an epithelial program mediated by PPARgamma","volume":"19","author":"Drori","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2020.104703_bib0285","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lfs.2015.01.033","article-title":"Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats","volume":"128","author":"Liu","year":"2015","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.phrs.2020.104703_bib0290","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.2337\/db09-0522","article-title":"Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice","volume":"58","author":"Li","year":"2009","journal-title":"Diabetes."},{"issue":"10","key":"10.1016\/j.phrs.2020.104703_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128708","article-title":"Konstandi M. Dopamine D2-Receptor antagonists down-regulate CYP1A1\/2 and CYP1B1 in the rat liver","volume":"10","author":"Harkitis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104703_bib0300","doi-asserted-by":"crossref","first-page":"113613","DOI":"10.1016\/j.bcp.2019.08.015","article-title":"M3 Muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK\u03b2\/AMPK pathway","volume":"169","author":"Jadeja","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2020.104703_bib0305","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/ijms17111865","article-title":"Berberine alleviates olanzapine-induced adipogenesis via the AMPK\u03b1\u2013SREBP pathway in 3T3-L1 cells","volume":"17","author":"Li","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2020.104703_bib0310","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.1152\/ajpendo.00502.2010","article-title":"Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism","volume":"300","author":"Oh","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.104703_bib0315","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.3390\/ijms19103238","article-title":"AMPK: An epigenetic landscape modulator","volume":"19","author":"Gongol","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bpc.2008.01.003","article-title":"The psychotropic drug olanzapine (Zyprexa\u00ae) increases the area of acid glycerophospholipid monolayers","volume":"134","author":"Steinkopf","year":"2008","journal-title":"Biophys. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2020.104703_bib0325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/tpj.2009.62","article-title":"Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol","volume":"10","author":"Kristiana","year":"2010","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.phrs.2020.104703_bib0330","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/s41598-018-31953-x","article-title":"Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPAR\u03b32","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819328579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819328579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:06:01Z","timestamp":1760911561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819328579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":66,"alternative-id":["S1043661819328579"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104703","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic histone modulations of PPAR\u03b3 and related pathways contribute to olanzapine-induced metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104703"}}